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Abstract: Prolonged caloric intake above energy needs disturbs the body’s ability to store and manage
the excess of energy intake, leading to the onset of chronic degenerative diseases. This study aimed to
compare the effect of three foods, which contain demonstrated bioactive compounds in the treatment
of obesity and as an adjuvant in obesity energy restriction treatments. In a mice obesity model induced
through a high-fat diet; fish oil, soluble fibre, and soy were incorporated to evaluate its capacity
to modulate metabolic factors in adipose tissue during a continued fat intake or weight reduction
through a normocaloric diet. As a result, fish oil improved mitochondrial related, adipose tissue
hormone expression, and oxidation products when high-fat diets are consumed; while soluble fibre
improved glucose and inflammation pathways during high-fat diet intake. In weight reduction
treatments few differential features, as a treatment adjuvant, were observed for fish oil and soy;
while soluble fibre was able to improve the weight reduction effects induced by a normocaloric
diet. As a conclusion, soluble fibre supplementation compared to an energy reduction program,
was the only treatment able to induce a significant additional effect in the improvement of weight
loss and adipose tissue metabolism.
Keywords: adipose tissue; fish oil; soluble fibre; soy; mitochondria; metabolism
1. Introduction
Severe obesity is an increasingly prevalent condition and is often associated with long-term
comorbidities, reduced survival, and higher healthcare costs. Although several resources have
been invested to treat and prevent obesity, an overall median success rate of 15% is observed in
most studies and intervention programs [1,2]. While pharmacological strategies are indicated for
patients with high cardiovascular risk, non-pharmacological treatments such as lifestyle interventions
(diet, physical exercise, stress management, and others) are indicated for a great majority of people with
overweight problems. This fact raises the interest of the health and scientific community to address
additional tools to act as adjuvants in the treatment of obesity, some of them based on food technological
modifications to induce satiety, while others through the addition of food bioactive compounds that
may improve insulin signaling pathways, the regulation of adiposity, energy expenditure, and/or
energy bioavailability [3].
Several studies indicate that fish oil and omega-3 polyunsaturated fatty acids supplements may
help to prevent cardiovascular and metabolic diseases due to their anti-inflammatory properties.
However, meta-analysis of clinical controlled trials does not show any improvement in body weight
and lean body mass [4], while others have observed an improvement in blood lipid and metabolic
parameters without significant changes in anthropometric parameters [5]. On the other hand, soy has
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been widely studied due to the quality of its protein and high isoflavone content. Lipogenesis inhibition
and increased fatty acid β-oxidation, which lead to the reduction of body fat depots, are mechanisms
of isoflavones action against obesity [6]. In this regard, significant effects in anthropometric parameters
have been observed in low doses and during a short period of supplementation (two to six months);
but adverse effects have been observed in overweight and obesity populations [7]. Lastly, fibre,
especially soluble fibre, is widely recommended as an anti-obesity agent due to its ability to interfere
with gut lipid absorption, satiety and satiation effect, and gut microbiota composition and activity
modulation through short-chain fatty acids production between others [8].
Notwithstanding the above, the main problem during the development of obesity and its further
co-morbidities is the body’s inability to manage energy overload, generally known as lipotoxicity [9].
Mitochondrial dysfunction in adipocytes possibly induced by lipotoxicity results in detrimental effects
on its differentiation, lipid metabolism, insulin sensitivity, and oxidative capacity between others
and has been reported to have a strong correlation with metabolic diseases, including obesity, type 2
diabetes and other metabolic diseases [10]. In this context, adipose tissue “healthy” metabolism is a key
feature for the success of weight reduction in patients with morbid obesity after bariatric surgery [11].
Nonetheless, the main problem in this context is how to improve the metabolic capacity of adipose
tissue of people with obesity that shows an unbalanced metabolism. Therefore, the main objective of
this study was to determine the possible adjuvant effect in the adipose tissue metabolic profile during
weight reduction-treatments of three recognized dietary treatments: Fish oil, soluble fibre, and soy;
in adipose tissue metabolism after the onset of obesity. A mice obesity model was employed where
transcriptomic and oxidative markers analyses were employed to determine changes in adipose tissue
metabolism induced by the selected dietary treatments.
2. Results
The study was conducted in two periods. In the first period, there was an induction of obesity
through a high-fat diet for four months with an observed mean increase in body weight of about 10 g
(58.8 ± 3.9 versus 48.3 ± 3.6 in animals fed with a high-fat diet and normocaloric diet, respectively)
(Figure 1A). Once overweight was induced, the treatment period started in which, different bioactive
compounds as adjuvants in weight reduction treatments were added to normocaloric and high-fat diets.
For a better understanding of the results from the present study, the behavior observed in
the overweight animals that were subjected to a normocaloric diet for two months (in order to reduce
weight) and the two controls of the study: (1) Animals that were always fed with a normocaloric diet;
and (2) overweight animals that continued during two months with a high-fat diet; will be described
firstly. As shown in Figure 1A, the gap in the weight of the animals fed during six months with
a high-fat and normocaloric diet continued increasing in this time period, with a mean difference
between the two groups of 12.5 g (64.6 ± 4.3 versus 52.1 ± 5.2, respectively). The treatment with
a normocaloric diet induced an accelerated weight reduction that was appreciable until week three of
treatment; later slight weight reductions were observed with a final difference between normocaloric
control group and normocaloric weight reduction group of 2.4 g. Concerning dietary intake (Table 1),
it was observed that a higher intake of the normocaloric diet, due to a lower energy density; compared
to the high-fat diet (0.55 versus 0.47 g/week/g body weight, respectively). However, from the energy
point of view, the amount of energy ingested was lower in the weight reduction group compared to
the two controls (2.1 ± 0.2, 2.7 ± 0.5, and 2.8 ± 0.7 kcal/week/g, respectively).
The weight reduction improved the capacity for homeostatic regulation of glucose as seen in
Figure 1B,C; where similar behaviors in the changes in blood glucose in the normocaloric control group
and normocaloric weight reduction group were observed in both tolerance tests. Despite the differences
in the capacity to regulate glycaemia, no differences in blood biochemical parameters were observed
between the three groups (Table 1), although the normocaloric treated group presented a healthier
lipid profile.
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Figure 1. Adipose tissue metabolic changes induced by a high-fat diet and a weight reduction treatment
through a normocaloric diet. Control: Mice fed with a normocaloric diet during the whole experimental
period; high-fat: Mice fed with a high-fat diet during the whole experimental period; normocaloric:
Mice fed with a high-fat diet during the first four months of experimentation and then fed with
a normocaloric diet during the next two months as a treatment period. Data are presented as the mean
± standard deviation. (A) Body weight evolution during the treatment period. (B) and (C) glucose
and insulin tolerance tests at the end of the experimental period. (D) Changes in the expression of
Cyba. Data were normalized with endogenous control 18S expression by 2−∆Ct. (E) Partial least-square
discriminant analysis of transcriptomic and oxidative stress variables. The importance of each variable
is represented in (F), squares on the right side of the graph represent the differences in the concentrations
between the three groups. Red, yellow, and green squares indicate higher, intermediate, and lower
concentrations, respectively of the variable in each group. * and ** denotes statistical difference with
the normocaloric control group (a) with p-values below 0.05 and 0.01, respectively.
To determine the effects on energy availability in different metabolic parameters in the adipose
tissue, a transcriptomic and protein oxidative damage analysis was performed. At the transcriptional
level, it is observed that the high-fat diet induces an increase in the levels of cytochrome b-245 alpha
(Cyba) (Figure 1D), a subunit of the enzyme complex NADPH oxidase, related to the generation
of oxidative stress. Despite this change, no differences were observed in protein oxidative stress
in the adipose tissue between normocaloric and high-fat diet controls (Table 2). Notwithstanding,
after the weight reduction through a normocaloric diet, a reduction in malondialdehyde-lysine
(MDAL) levels, a marker of oxidative protein damage from fat peroxidation, was observed. Regarding
the other transcriptional parameters analyzed, no significant differences were observed between
normocaloric, high-fat, and normocaloric treated diet group (Supplementary Figure S1). To determine
if the transcriptional and protein oxidative stress parameters could discriminate metabolic differences in
adipose tissue between the three groups, a partial least square-discriminant analysis (PLS-DA) analysis
was performed (Figure 1E,F). It is observed that the differences in selected RNA and oxidative stress
levels can differentiate between the three experimental groups with a probability of 61% (random forest
OOB = 0.389), being high levels of Tnfa, Nrf1, Tfam, CML, and Pparg the ones that best characterize
overweight animals that were subsequently treated with a normocaloric diet.
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body weight) 0.69 ± 0.12 0.47 ± 0.11
a**** 0.55 ± 0.06a** 0.41 ± 0.03 a**** 0.47 ± 0.05a**** 0.44 ± 0.01a**** 0.53 ± 0.03a** 0.55 ± 0.04a** 0.55 ± 0.05a**
Glucose (mg/dL) 172 ± 25 197 ± 62 155 ± 15 171 ± 16 160 ± 14 194 ± 53 157 ± 11 160 ± 17 166 ± 16
Cholesterol (mg/dL) 215 ± 61 227 ± 61 189 ± 55 208 ± 50 160 ± 23 195 ± 27 130 ± 30a** 135 ± 20a* 173 ± 30
HDL-cholesterol (mg/dL) 120 ± 22 117 ± 23 106 ± 24 117 ± 25 106 ± 13 139 ± 24 89 ± 9 100 ± 12 120 ± 7
LDL-cholesterol (mg/dL) 92 ± 25 104 ± 25 103 ± 45 98 ± 24 90 ± 9 120 ± 30 47 ± 14a*,b** 83 ± 22 103 ± 18
Triacylglycerides (mg/dL) 69 ± 23 63 ± 20 75 ± 17 70 ± 22 86 ± 8 69 ± 25 74 ± 28 68 ± 15 85 ± 27
Antioxidant capacity (FRAP)
(µmol Trolox equivalents) 215 ± 65 322 ± 70 222 ± 76 272 ± 120 213 ± 39
c* 238 ± 50 217 ± 59 240 ± 30 213 ± 59
Values are reported as the mean ± standard deviation. Differences between groups were determined by one-way ANOVA and multiple comparisons were performed comparing the mean
of each group with the mean of the control normocaloric (a), control high-fat (b) and treatment normocaloric (c) diets. Correction for multiple comparisons was performed with Dunnett
test and p-values below 0.05 (marked in bold) were considered as a significant difference between groups (* p < 0.05, ** p < 0.01, and **** p < 0.0001).













High-Fat Diet + Soy
Treatment
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Normocaloric Diet + Soy
Semialdehyde glutamic 7134 ± 222 5784 ± 1007 6745 ± 632 4642 ± 95a** 13406 ± 734a****,c**** 14197 ± 2418a****,c**** 5969 ± 271 14943 ± 1256a****,b**** 12789 ± 1606a****,b****
Nε-(Carboxiethyl)lysine 345 ± 48 314 ± 57 342 ± 35 333 ± 68 419 ± 71 350 ± 86 383 ± 64 401 ± 45 363 ± 94
Malondialdehyde lysine 629 ± 104 566 ± 55 342 ± 101a*** 275 ± 90a**** 314 ± 113a**** 258 ± 125a**** 479 ± 164 535 ± 19 358 ± 108a***,b*
Nε-(Carboximethyl)lysine 1539 ± 122 1709 ± 323 1752 ± 137 1660 ± 140 2853 ± 329 2579 ± 361 1745 ± 138 2385 ± 334 2407 ± 562
2-succinyl-cysteine 43.6 ± 4.8 44.6 ± 7.2 42.3 ± 6.5 44.6 ± 8.9 46.4 ± 9.2 41.0 ± 1.4 42.3 ± 7.6 46.5 ± 2.1 42.5 ± 4.8
Values (µmol/mol of lysine) are reported as the mean ± standard deviation. Differences between groups were determined by one-way ANOVA and multiple comparisons were performed
comparing the mean of each group with the mean of the control normocaloric (a), control high-fat (b) and treatment normocaloric (c) diets. Correction for multiple comparisons was
performed with Dunnett test and p-values below 0.05 (marked in bold) were considered as a significant difference between groups (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001).
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The differences in energy intake and availability induced changes in the number of mitochondria
in the adipose tissue. Compared with the control group, a higher level of mtDNA was observed in
the mice fed with a high-fat diet, while similar amounts were observed with the normocaloric diet
treated group (Figure 2A). Despite the increase in mtDNA, the ratio porin/mtDNA was lower in
the mice fed with a high-fat diet; while mice treated with a normocaloric diet showed increased ratios
of porin/mtDNA (Figure 2B).
Figure 2. Changes in mtDNA and porin levels in adipose tissue. (A) mtDNA content, data was
normalized with nuclear gene 18S as the endogenous control. The expression was calculated by 2−∆Ct.
(B) Porin content was determined by western blot. The levels of porin were normalized by the amount
of mtDNA. HF = high-fat diet, NC = normocaloric diet, FO = fish oil, SF = soluble fibre, and S = soy.
*, **, and **** denotes statistical difference with the control group with p-values below 0.05, 0,01,
and 0.0001, respectively.
Concerning the effect of the bioactive compound (soy, fibre, and fish oil) supplementation during
a high-fat feeding in overweight mice; it was observed that none of the bioactive foods had a significant
effect in the prevention of the increase in body weight gain induced by the high-fat diet (Figure 3A).
Similarly, no significant differences were observed in blood biochemistry parameters, except for
a reduction in plasma antioxidant capacity observed in the soluble fibre treated group (Table 1).
Regarding glucose homeostatic behavior, soluble fibre incorporation to a high-fat diet, induced a better
capacity to regulate blood glucose levels (Figure 3B,C) in both glucose and insulin tolerance tests;
while the treatments with fish oil and soy did not show significant differences. At a transcriptional
level, it was observed that fish oil treatment induced higher levels of Cyba (Figure 3D), Fasn, and Lep
(Supplementary Figure S1) compared to the high-fat diet control group. About oxidative damage,
soluble fibre and soy treatments increased SAG and decreased MDAL levels; while fish oil induced
a decrease in both markers of oxidative protein modifications. In addition to the slight difference
between the three groups in the levels of almost all analyzed parameters, the PLS-DA analysis showed
that it is possible to discriminate the belonging of the adipose tissue within the three treatments groups
with a probability of 94% (random forrest OOB = 0.0556), especially between fish oil and soluble
fibre-soy treated groups (Figure 3E). The main variables that explain these differences are the higher
levels of Lep, Fasn, Tfam, Adipoq, Cyba, and Nrf1 and lower levels of SAG and CML observed in the fish
oil treated group compared with soy and soluble fibre (Figure 3F).
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Figure 3. Adipose tissue metabolic changes induced by the treatment with fish oil, soluble fibre, and soy
during the consumption of a high-fat diet. Data are presented as the mean ± standard deviation.
(A) Body weight evolution during the treatment period. (B) and (C) glucose and insulin tolerance tests
at the end of the experimental period. (D) Changes in the expression of Cyba. Data were normalized
with endogenous control 18S expression by 2−∆Ct. (E) Partial least square-discriminant analysis of
transcriptomic and oxidative stress variables. The importance of each variable is represented in (F),
squares on the right side of the graph represent the differences in the concentrations between the three
groups. Red, yellow, and green squares indicate higher, intermediate, and lower concentrations,
respectively of the variable in each group. *, ** and *** denotes statistical difference with the control
high-fat group with p-values below 0.05, 0.01 and 0.001 respectively.
Bioactive foods induced changes in the levels of mtDNA mainly a lower amount in the fish oil,
a higher amount in soluble fibre, and no modifications in soy groups. Regarding the porin/mtDNA ratio,
higher ratios were observed in the fish oil and soy group, while soluble fibre induced a lower
porin/mtDNA ratio (Figure 2).
Finally, the adjuvant effect of fish oil, soluble fibre and soy incorporated in normocaloric diet to
induce weight reduction did not show differences in the magnitude of weight reduction compared
with the normocaloric diet alone; although the soluble fibre normocaloric diet was the treatment
that induced the highest weight reduction between the four groups (Figure 4A). Notwithstanding,
appreciable differences were observed in blood biochemistry parameters where fish oil and soluble fibre
induced higher reductions in total cholesterol, and additionally a reduction in LDL-cholesterol levels by
fish oil. The incorporation of soluble fiber into the normocaloric diet provides additional improvement
in glycemic homeostasis, observed both from the glucose and insulin tolerance tests (Figure 4B,C).
In relation to protein oxidative damage, it was observed that the incorporation of soluble fiber and soy
induced an increase in SAG, and decrease in MDAL levels by soy (Table 2); while the levels of Fasn,
Pparg, Adipoq, and Dgat1 were significantly increased with the addition of soluble fiber (Supplementary
Figure S1). Unlike the previous observations, none of the adjuvant treatments induced a difference in
the expression of Cyba (Figure 4D). Finally, transcription factors and the markers of protein oxidation
were able to discriminate adipose tissues of the animals subjected to the different treatments with
a probability of 83% (random forest OOB = 0.167), mainly between fish oil and soluble fibre-soy treated
groups. Among the parameters that allow to discriminate between the three groups, the treatments
with soy induced higher levels of SAG, CML, and 2SC, while soluble fibre induced higher levels of Irs1
and Dgat1; and fish oil with higher levels of MDAL (Figure 4E,F).
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Regarding the induced changes in mitochondria, when the selected dietary compounds were
incorporated in the normocaloric diet, an increase in the levels of mtDNA and a reduction in the levels
of porin/mtDNA ratio was observed in all groups (Figure 2).
Figure 4. Adipose tissue metabolic changes induced by the treatment with fish oil, soluble fibre, and soy
during the consumption of a normocaloric diet. Data are presented as the mean ± standard deviation.
(A) Body weight evolution during the treatment period. (B) and (C) glucose and insulin tolerance tests
at the end of the experimental period. (D) Changes in the expression of Cyba. Data were normalized
with endogenous control 18S expression by 2−∆Ct. (E) Partial least square- discriminant analysis of
transcriptomic and oxidative stress variables. The importance of each variable is represented in (F),
squares on the right side of the graph represent the differences in the concentrations between the three
groups. Red, yellow, and green squares indicate higher, intermediate, and lower concentrations,
respectively of the variable in each group. * denotes statistical difference with the control nomocaloric
group with p-values below 0.05.
Due to the complexity of the results, a brief review of the main effects of each treatment in
different pathways in adipose tissue metabolism is described in Figure 5. For instance, fish oil seems
to be a good candidate to improve mitochondrial related and adipose tissue hormone expression;
and a reduction in oxidation products when high-fat diets are consumed. While soluble fibre may
improve glucose and inflammation pathways during high-fat diet intake. In weight reduction treatments
by energy adequacy through a normocaloric diet few differential features as a treatment adjuvant
were observed for fish oil, soy, or soluble fibre. Soy incorporation may increase transcriptional factors
related to mitochondria, while fish oil and soluble fibre may reduce parameters related to oxidation
and inflammation, respectively.
3. Discussion
The objective of this study was to compare the effectiveness of different bioactive foods in the ability
to reduce body weight when obesity and metabolic impairments are established; and the effect they
would have on adipose tissue metabolism. Three foods that are a source of bioactive compounds
were selected, such as soy (source of isoflavones, protein fraction, among others), fish oil (source of
omega-3 fatty acids), and soluble fibre from Psyllium platago ovata. The three sources of bioactive
compounds have been described in both animal models and humans, as foods capable of preventing
and treating insulin resistance in obesity situations. However, the mechanisms of action described
are different for each one of them, for example, omega 3 fatty acids are anti-inflammatory agents;
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soluble fibre through physical mechanism influencing satiety and energy absorption of food, as well
as physiological through colonic fermentation by-products; while soy could improve insulin secretion
and sensitivity [12]. In general terms, it was observed in this study that except soluble fibre, neither soy
nor fish oil were able to reverse the adverse effects of a high-fat diet, nor did they show an adjuvant
effect in normocaloric dietetic treatment. Although logically, it is observed that the most effective
treatment for situations of obesity and insulin resistance was the reduction of energy intake.
Figure 5. Schematic representation of the involvement of each analyzed bioactive food in adipose tissue
metabolism. Green and red arrows represent the main effects of each bioactive food in the represented
metabolic pathways. Green color identifies the bioactive food with a higher impact, while red color
identifies the compound with minor effects in the pathways. A brief description of the pathways
is the following: Insulin receptor substrate-1 (IRS-1) is phosphorylated after the stimulation of
the insulin receptor and initiates insulin signaling which will induce glucose uptake by GLUT4
transporter (Glucose transporter). During the metabolization of glucose some by products may
be produced such as carboxyethyl-lysine (CEL) (from methylglyoxal) and 2-succinyl-cysteine (2SC)
(from fumarate). Acetyl-CoA could serve as an initial metabolite for the novo-lipogenesis, in which
fatty acid synthase (FASN) and diacylglycerol acyltransferase-1 (DGAT1) are necessary for free
fatty acid (FFA) and triacylglycerides (TG) synthesis, respectively, with its further incorporation
into the lipid droplet and release for energy source is regulated by Perilipin-1 (PLIN1). Leptin (LEP)
and adiponectin (ADIPOQ) are hormones secreted mostly in relation to the energy stored in the adipocyte
and serve as signaling molecules for body’s energy homeostasis regulation. Mitochondrial Transcription
Factor A (TFAM) and nuclear respiratory factor-1 (NRF1) are proteins implicated in mitochondrial
DNA transcription and replication, which may modify the number and morphology of the mitochondria
and its components such as cytochrome b-245 alpha (CYBA). Impaired mitochondrial activity may lead to
the increase in oxidative stress compounds such as malondialdehyde-lysine (MDAL) and semialdehyde
glutamic (SAG), which in some cases may induce inflammation with increased levels of tumor necrosis
factor alpha (TNFα) and interleukin-6 (IL-6).
The reduction of energy intake, by itself, tends to induce metabolic changes in adipose tissue
related to mitochondria factors, based on the PLS-DA analysis such as higher levels of Nrf1, Tfam,
and Pparg. However, the observed effect, no changes were observed in the levels of mtDNA between
the normocaloric controls and the obese mice subjected to weight reduction through a normocaloric
diet. Likewise, an increase in mtDNA levels was observed in obese mice fed with a high-fat
diet. Suggesting that the similarity in the content in mtDNA in the normocaloric treated mice
compared to the normocaloric control may represent a healthy feature. However, the increase in
the ratio of porin/mtDNA observed in the normocaloric treated group suggests that this group
may have a higher metabolic rate compared to normocaloric and high-fat controls. Since porin
(also called voltage-dependent anion channel, VDAC) regulates the transport of all metabolites
that enter and leave the mitochondria (except for a relatively few membrane-permeant lipophilic
compounds such as oxygen, acetaldehyde, short-chain fatty acids); the increase of its content may
suggest an increase in mitochondrial metabolic capacity [13]. Similar results have been reported in
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humans on the effect of weight reduction in adipose tissue, where an increase in the expression of
genes related to oxidative phosphorylation, tricarboxylic acid cycle, and fatty acid beta-oxidation has
been observed [14]. This greater capacity for energy metabolism is reflected in the energy intake of
normocaloric treated overweight animals, where they consumed on average fewer calories per g of
weight (2.13 kcal/g body weight) than mice with high-fat diets (2.43 kcal/g body weight) and control
mice exposed throughout the treatment period to a normocaloric diet (2.67 kcal/g body weight).
Suggesting in this way, the use of energy reserves of adipose tissue as a compensatory source to
the reduced energy obtained by the diet. As shown in Table 1, the addition of fish oil and soy
to normocaloric diets did not induce significant changes in energy intake (values between 2.05 to
2.13 kcal/g of body weight, respectively) nor body weight; while soluble fibre reported the lowest
energy intake, highest weight reduction, and better homeostatic capacity of glucose metabolism.
This suggests that the regulation of energy availability may be a key factor for obesity and its metabolic
imbalance treatment. It is necessary to mention that the exposure to high-fat diets for four months
was enough to induce metabolic inflexibility conditions; where the reduction of body weight may be
impaired due to the disability of energy utilization [15].
In this sense, the next question is whether these bioactive foods may have a treatment effect in
established obesity when high-energy intake is persistent. In this situation, the diet supplementation
with soluble fibre seems to be the best treatment. It was observed that a better ability to regulate
glucose homeostasis and to induce a slight reduction in body weight gain compared with other
experimental groups. These effects are also described in humans. In a recent meta-analysis, a reduction
of 0.84 points in the BMI, 0.41% in the percentage of body fat and 2 cm in the waist circumference
is observed due to soluble fibre consumption [16]. Concerning the adipose tissue metabolism,
this capacity to reduce body weight could be explained by an improvement in the capacity of glucose
metabolism evidenced by higher levels of Irs1, CEL, and 2SC; and the greater sensitivity to glucose
and insulin tolerance tests. This behavior has also been observed in humans, where patients with higher
levels of CEL and 2SC in adipose tissue, have a greater capacity for weight reduction after bariatric
surgery [11]. About the transcription factors related to mitochondria, based on the PLS-DA analysis
soluble fibre treatment was characterized to present the lowest levels of Tfam. This observation
may be contradictory since adipose tissue in obesity tends to be characterized by mitochondrial
dysfunction [17]. Although TFAM is necessary for the stability of mtDNA and the initiation of
transcription and replication of mtDNA, some authors suggest that its downregulation in situations
of high-fat diets could be related to a greater mitochondrial oxidation capacity and higher oxygen
consumption [18]. The mechanism of action by which soluble fibre induces an improvement when
high-fat diets are taken, could be related either to the decrease in energy availability [19] or to the indirect
effects of colonic fermentation products. In this sense, it has been observed that oral butyric acid
can prevent the insulin resistance induced by high-fat diets, by an increase in the capacity of energy
metabolization [20].
Fish oil, on the other hand, is the treatment with the most differential characteristics with respect
to soluble fibre and soybean treatments (Figure 3E). It is characterized, based on the PLS-DA analysis
by having lower levels of oxidative damage (MDAL, CML, SAG); and higher levels of transcription
of Lep and Adipoq; inflammation (Tnfa, Il6); and genes related to the mitochondria (Tfam, Nrf1,
and Cyba). Possibly the main effect of omega 3 fatty acids in the adipose tissue is to favor its
expansion capacity, reflected by higher levels of Fasn and Lep in high-fat diets. This effect may
be related to the anti-inflammatory capacity of the omega-3 fatty acids previously described in
several studies [21,22], which induce higher levels of pro-resolving lipid mediators such as resolvins,
protectins, and maresins. However, although it has a better transcriptional and oxidative damage
profile, no significant differences are observed in the homeostatic capacity to regulate the glycemia
observed in both glucose and insulin tolerance tests, or to prevent weight gain. Which suggests that
the observed changes in mtDNA and porin/mtDNA ratio are not related to an improvement in energy
homeostasis. Similar results have been observed in humans [23] and in mice where supplementation
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with eicosapentaenoic acid does not prevent weight gain in high-fat diets, or induce changes in oxygen
consumption [24], and similar behaviors have been observed in other tissues such as skeletal muscle [25].
Finally, supplementation with soy did not show significant improvements compared to the high-fat
diet. The potential discrepancy of these results with those previously published may be derived from
the complexity in the nutritional composition of soybeans. For example, differences in the impact on
body weight have been observed in treatments with soy and isoflavones [7]. Although isoflavones
demonstrate anti-obesity properties, soy in obese subjects and when consumed in high quantities may
induce an increase in body weight.
Some limitations of this study can be raised. Although there were observable differences in
the transcriptomic profile, some of these changes in its levels may not be translated to real situations due
to the regulation of protein expression or mitochondrial functionality. In this sense, different profiles of
mtDNA were observed between treatments and no relationships were observed between the molecular
changes and the homeostatic capacity to regulate glucose metabolism. Therefore, it is suggested for
further studies to perform additional analyses of mitochondrial enzyme activity, protein expression,
and/or respiratory capacity to determine the metabolic capacity of the adipose tissue. Moreover,
the influence of the studied compounds in other organs and systems involved in energy metabolism
such as liver and muscle are not addressed in this study. For example, it has been observed that
normocaloric diet increase muscle Glut4 mRNA levels in obese mice [26]. This is particularly important
since not all organs and systems respond in a similar way to an increase or decrease in energy
availability. Similarly, in the clinical setting, the effect of a mild reduction in body weight induces
a quick switch from a disease to a clinically non-pathological condition. However, in this respect,
frailty from this condition is observed if there is an increase in body weight. This implies that although
some biomarkers are normalized during weight reduction programs, the metabolic system is unstable
and liable to return to a disease condition. In other words, some organs may still have metabolic
inflexibility, explaining in this way the deleterious effects of “yo-yo” dieting [27]. Notwithstanding,
based on the information collected in this model, it is possible to conclude that besides soluble fibre,
the diet supplementation of the selected bioactive foods, compared to an energy reduction program,
does not induce a significant additional effect in the improvement of adipose tissue metabolism.
4. Materials and Methods
4.1. Animals and Diets
Three-week-old male CD1 Swiss (initial weight 22.1 ± 1.9) mice obtained from Harlan Laboratories
(Catalunya, Spain) were maintained at 23 ± 2 ◦C under a 12:12 h light-dark cycle (lights on from
07:00 to 19:00). All mice were allowed unlimited access to in-house produced high-fat (Experimental
and high-fat control group n = 48) or normocaloric diet (Control group n = 6) for four months. After that
period, 24 animals that were fed with a high-fat diet were randomly assigned to a normocaloric diet
(weight reduction control group n = 6) and a normocaloric diet + dietary bioactive compounds mainly
fish oil (Sigma-Aldrich, F8020 Lot#051M1861V, St-Louis, MO, USA), soy (Vivesoy, Grupo Leche Pascual,
Aranda del Duero, Spain), and soluble fibre from psyllium plantago (Laboratorios Normon S.A.,
Madrid, Spain) (n = 6 for each experimental group) for two months. The other half of the animals
continued to be exposed to a high-fat diet (High-fat control group n = 6) and high-fat diet + dietary
bioactive compounds mainly fish oil, soy, and soluble fibre (n = 6 for each experimental group)
for two months. Sample size was estimated with an accepted risk of 0.05 and an estimated power
of 90%. It was considered that the treatment would be effective if it induces a reduction of 6.5 g of
body weight in the following two months of treatments; and a standard deviation of body weight
of 3.6 g was used for sample calculation (estimated n = 5.25). The scheme of the experimental
procedure is described in Supplementary Figure S2, and the dietary and nutritional composition of
experimental diets are described in Supplementary Table S1. Body weight, food and beverage intake
were measured weekly throughout the study. At the end of the experimental period, subcutaneous
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glucose and insulin tolerance tests were performed (see below). Further, all animals were sacrificed
and epididymal fat pad (visceral adipose tissue) was collected, frozen in liquid nitrogen, and stored
at –80 ◦C. All animal procedures followed the approved protocols from the Institutional Animal Care
and Use Committee and by the Ethics Committee of the University of Lleida (Approval number:
CEEA 18-01/12; date: 2/2/2012).
4.2. Subcutaneous Glucose and Insulin Tolerance Tests
Mice were fasted for 12 or 2 h and then injected subcutaneously with glucose (2 g/kg body weight)
or insulin (0.5 U/kg body weight, Sigma I0516 from bovine pancreas), respectively, with a rest period
of five days between both tests. Blood samples were taken every 20 min (0–120 min) from the tail
vein and blood glucose levels were determined with a portable glucometer (Roche Accu-Chek Aviva,
CAT/TYP 05911982002, Mannheim, Germany). The area under the curve was calculated as the sum of
trapezoids in both tests.
4.3. Adipose Tissue Homogenization
Samples were homogenized in a buffer containing 20 mM Tris pH:8, NaCl 150 mM, 2 mM EDTA,
1% Triton X-100, 10% Glycerol, 1 µM butylated hydroxyl toluene, 10 µg/mL aprotinin, 1 mM NaF, 1 mM
Na3VO4, and a protease inhibitor mix (GE Healthcare 80-6501-23, Chicago, IL, USA) (1% v/v) with
a Potter-Elvehjem device, at 4 ◦C. After samples were centrifuged (14,000 rpm, 20 min, 4 ◦C) the lower
phase was collected for further analysis. Protein concentrations were measured using the Bradford
protein assay (BioRad Laboratories, München, Germany).
4.4. Analysis of Protein Oxidative Modifications
Glutamic semialdehydes (GSA), glycoxidation (carboxyethyl-lysine (CEL) and carboxymethyl-lysine
(CML)), lipoxidation (Malondialdehyde-lysine, MDAL) and 2-succinocystein (2SC) were determined by
GC/MS as trifluoroacetic acid methyl esters derivatives in acid-hydrolyzed delipidated and reduced protein
samples using a HP6890 Series II gas chromatograph (Agilent, Barcelona, Spain) with a MSD5973A Series
and a 7683 Series automatic injector with a Rtx-5MS Restek column (30 m × 0.25 mm × 0.25 µm).
Quantification was performed by internal and external standardization using standard curves constructed
from mixtures of deuterated and non-deuterated standards. Analyses were carried out by selected
ion monitoring GC/MS (SIM-GC/MS). The ions used were: Lysine and [2H8]lysine, m/z 180 and 187,
respectively; 5-hydroxy-2-aminovaleric acid and [2H5]5-hydroxy-2-aminovaleric acid (stable derivatives
of GSA), CML and [2H4]CML, m/z 392 and 396, respectively; CEL and [2H4]CEL, m/z 379 and 383,
respectively, MDAL and d8-MDAL, m/z 474 and 482, respectively; and 2SC and d2-2SC, m/z 284 and 286.
The amounts of products are expressed as the µmolar ratio of GSA, CML, CEL, MDAL, and 2SC per mol
of lysine.
4.5. RNA Purification and Gene Expression Measurements
RNA was prepared using RNeasy Lipid Tissue Mini Kit (Qiagen, Izasa, Barcelona, Spain).
The integrity of each RNA sample was checked by the Agilent Bioanalyzer (Agilent Technologies,
Palo Alto, CA, USA). Total RNA was quantified by a spectrophotometer (GeneQuant; GE Health Care,
Piscataway, NJ, USA) reverse transcribed to cDNA with the High Capacity cDNA Archive Kit (Thermo
Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. Gene expression
was assessed by real-time PCR with a LightCycler 480 Real-Time PCR System (Roche Diagnostics,
Barcelona, Spain), using TaqMan and SYBR green technology suitable for relative gene expression
quantification. TaqMan probes for Fasn, Pparg, Irs1, Adipoq, Lep, Plin1, Dgat1, Tfna, Il6, Cyba, Tfam,
Nrf1, and 18S are detailed in Supplementary Material Table S2. The RT-PCR reaction was performed
in a final volume of 12 µL. The cycle program consisted of an initial denaturing of 10 min at 95 ◦C
then 40 cycles of 15 s denaturing phase at 95 ◦C and 1 min annealing and extension phase at 60 ◦C.
Fold changes compared with the endogenous control were then determined by calculating 2−∆Ct.
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The gene expression results are expressed as the expression ratio relative to 18S gene expression
according to the manufacturer’s guidelines. No difference in the expression of 18S was observed
between groups (p = 0.1848).
4.6. Antioxidant Capacity
Antioxidant capacity was measured by the Ferric Reducing Antioxidant Power (FRAP) method.
Briefly, 900 µL of the FRAP reagent, containing, 2,4,6-Tris(2-pyridyl)-s-triazine, FeCl3, and acetate
buffer, was mixed with 90 µL of distilled water and 30 µL of the test sample or the blank (solvents used
for homogenization). Maximum absorbance values taken at 595 nm were taken every 15 s at 37 ◦C.
The readings at 30 min were selected for calculations of FRAP values. Solutions of known Trolox
(Sigma-Aldrich, 238813, USA) concentration were used for antioxidant capacity equivalents.
4.7. Blood Biochemical Analysis
Blood biochemical profile was determined by an enzymatic spectrophotometric test from Spinreact
(St. Esteve de Bas, Spain) following the manufacturer’s instructions with the following analysis kits:
Total-cholesterol (1001095); HDL-cholesterol (1001096); LDL-cholesterol (41023); and triacylglycerides
(1001312).
4.8. Western Blot Analysis
Total protein (15–40 µg) was resolved by SDS-PAGE and electroblotted onto polyvinylidene
difluoride membranes (Immobilon-P Millipore, Bedford, MA, USA). Immunodetection was performed
using as primary antibody porin (A31855, Molecular Probes, Eugene, OR, USA). A monoclonal
antibody to β-actin (Sigma, USA) was used to control protein loading. Protein bands were visualized
with the chemiluminescence ECL method (Millipore Corporation, Billerica, MA, USA). Luminescence
was recorded and quantified in a Lumi-Imager equipment (Boehringer, Mannheim, Germany),
using the Quantity One 4.6.5. software (Bio-Rad, Hercules, CA, USA).
4.9. Statistical Analysis
Data is presented as the mean ± standard deviation. Analysis of Gaussian distribution of all
variables was performed by D’Agostino–Pearson omnibus normality test. The statistical significance
comparison of variables with normal Gaussian distribution was calculated by one-way ANOVA.
Multiple comparisons were performed comparing the mean of each group with the mean of the control
normocaloric and correction for multiple comparisons was performed with Dunnett test. Non-normal
Gaussian distribution was analysed by Kruskall–Wallis test with Dunn’s as a post-hoc test. In both
cases, p-values below 0.05 in all statistical tests employed were considered as statistically significant.
Partial least square-discriminant analysis (PLS-DA) was performed with transcriptomic and oxidative
stress data to determine main differences between groups. Data was normalized by auto-scaling
(mean-centred and divided by the standard deviation of each variable) for the PLS-DA analysis.
Random forrest out-of-bag error (OOB) was performed to determine the probability that the variables
employed in the PLS-DA analysis may discriminate the belonging of each animal to each group.
Variable importance in projection (VIP scores) determined by the weight of the sum of squares of PLS
loadings; was used to classify the main variables that contributed to the differences between groups.
GraphPad Prism (version 5.0) and MetaboAnalyst (version 3.0) were used for statistical analysis
and graph plotting.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/23/
5870/s1.
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Cyba Cytochrome b-245 alpha
Dgat1 Diacylglycerol Acyltransferase-1










Nrf1 Nuclear respiratory factor-1
OOB Random Forrest Out-of-bag
Plin1 Perilipin 1
PLS-DA Partial least square-discriminant analysis
Pparg Peroxisome proliferator-activated receptor gamma
S Soy
SF Soluble fibre
Tfam Mitochondrial transcription factor A
Tnfa Tumor necrosis factor alpha
VIP Variable importance projection
2SC 2-succinyl-cysteine
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